Anergis SA
BiopĂ´le  III
Route de la Corniche 9B
CH-1066 Epalinges
Tel: +41- 21 651 92 20
Fax: +41 21 651 92 21

Welcome to Anergis



Anergis is a clinical-stage biopharmaceutical company based in Switzerland.

Anergis discovers and develops proprietary synthetic allergy vaccines with the aim to provide allergy patients and doctors with a significantly improved treatment option: ultra-fast desensitization.

Anergis COP allergy vaccines are pharmaceutical-grade products based on Contiguous Overlapping Peptides (COPs) and only need to be administered for 2 months in order to achieve long-lasting desensitization.

If you are interested to participate in one of our clinical trials, please send an email to

Upload company presentation


19 December 2014
Anergis Granted U.S. Patent for Ragweed Allergy Vaccine AllerR

11 December 2014
Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT

03 December 2014
Anergis Closes Series B Financing Round Totaling CHF 14.5 Million

16 September 2014
Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT

03 June 2014
Anergis Appoints Dr. Vanya Beltrami as Director Product Development

27 May 2014
Anergis to Present New COP Allergy Vaccine Data at EAACI Conference 2014 in Copenhagen

see details